JP2019509714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509714A5 JP2019509714A5 JP2018533864A JP2018533864A JP2019509714A5 JP 2019509714 A5 JP2019509714 A5 JP 2019509714A5 JP 2018533864 A JP2018533864 A JP 2018533864A JP 2018533864 A JP2018533864 A JP 2018533864A JP 2019509714 A5 JP2019509714 A5 JP 2019509714A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- pcsk9
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 66
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 66
- 239000012634 fragment Substances 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 230000035772 mutation Effects 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000004602 germ cell Anatomy 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 2
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 2
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102220467177 Epsin-2_R72A_mutation Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102220468699 Protein arginine N-methyltransferase 3_Y87F_mutation Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 102220346089 c.113G>A Human genes 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000037998 chronic venous disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 102200004706 rs1060505034 Human genes 0.000 claims 1
- 102220051014 rs141837529 Human genes 0.000 claims 1
- 102220048364 rs200735877 Human genes 0.000 claims 1
- 102200118280 rs33918343 Human genes 0.000 claims 1
- 102200087445 rs566961335 Human genes 0.000 claims 1
- 102220054390 rs727505023 Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610010241.3 | 2016-01-05 | ||
| CN201610010241 | 2016-01-05 | ||
| PCT/CN2016/112075 WO2017118307A1 (zh) | 2016-01-05 | 2016-12-26 | Pcsk9抗体、其抗原结合片段及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509714A JP2019509714A (ja) | 2019-04-11 |
| JP2019509714A5 true JP2019509714A5 (OSRAM) | 2020-02-06 |
Family
ID=59273241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533864A Pending JP2019509714A (ja) | 2016-01-05 | 2016-12-26 | Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200270365A1 (OSRAM) |
| EP (1) | EP3401336A4 (OSRAM) |
| JP (1) | JP2019509714A (OSRAM) |
| CN (1) | CN107531795B (OSRAM) |
| WO (1) | WO2017118307A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018291702A1 (en) * | 2017-06-30 | 2020-02-06 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising PCSK-9 antibody and use thereof |
| KR102869563B1 (ko) | 2017-07-17 | 2025-10-10 | 얀센 바이오테크 인코포레이티드 | 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법 |
| US20230108572A1 (en) | 2020-03-19 | 2023-04-06 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Method For Treating Cholesterol-Related Diseases |
| CN119453139A (zh) * | 2024-10-30 | 2025-02-18 | 西安交通大学医学院第一附属医院 | 一种动脉粥样硬化的ob/ob肥胖小鼠模型及其构建方法与应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| TWI445716B (zh) * | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Ｐｃｓｋ９拮抗劑類 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| BR112012022917A2 (pt) | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
| WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
| US20140121123A1 (en) | 2010-10-29 | 2014-05-01 | Kevin Caili Wang | Methods for diversifying antibodies, antibodies derived therefrom and uses thereof |
| SG191219A1 (en) | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
| MX347602B (es) | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
| KR20140006022A (ko) | 2011-02-11 | 2014-01-15 | 아이알엠 엘엘씨 | Pcsk9 길항제 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| WO2012170607A2 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Use of pcsk9 antagonists |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| WO2013008185A1 (en) | 2011-07-14 | 2013-01-17 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| AR087715A1 (es) * | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| PL4252857T3 (pl) | 2011-09-16 | 2025-03-03 | Regeneron Pharmaceuticals, Inc. | Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9) |
| US9879093B2 (en) * | 2011-12-20 | 2018-01-30 | Adaerata, Limited Partnershp | Single domain antibodies as inhibitors of PCSK9 |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| NZ702315A (en) | 2012-05-17 | 2016-10-28 | Cyon Therapeutics Inc | Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors |
| EP2861624A1 (en) * | 2012-06-15 | 2015-04-22 | F. Hoffmann-La Roche AG | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
| JP6309521B2 (ja) * | 2012-08-13 | 2018-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体 |
| WO2014209384A1 (en) * | 2013-06-28 | 2014-12-31 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolema |
| MX374276B (es) * | 2014-02-28 | 2025-03-06 | Affiris Cvd Gmbh | Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9). |
-
2016
- 2016-12-26 US US16/067,951 patent/US20200270365A1/en not_active Abandoned
- 2016-12-26 JP JP2018533864A patent/JP2019509714A/ja active Pending
- 2016-12-26 EP EP16883432.3A patent/EP3401336A4/en not_active Withdrawn
- 2016-12-26 CN CN201680013088.8A patent/CN107531795B/zh active Active
- 2016-12-26 WO PCT/CN2016/112075 patent/WO2017118307A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2024026132A5 (OSRAM) | ||
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| JP2015503909A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| FI3625259T3 (fi) | Anti-sirp-alfa vasta-aineet | |
| JP2018521691A5 (OSRAM) | ||
| JP2014526898A5 (OSRAM) | ||
| JP2012070737A5 (OSRAM) | ||
| JP7292526B2 (ja) | 操作された抗ｉｌ－２抗体 | |
| JP2017052784A5 (OSRAM) | ||
| JP2016135783A5 (OSRAM) | ||
| JP2014511179A5 (OSRAM) | ||
| JP2020514277A5 (OSRAM) | ||
| JP2020522280A5 (OSRAM) | ||
| JP2014508511A5 (OSRAM) | ||
| JP6949012B2 (ja) | Ｂ型肝炎表面抗原に対する抗体及びその使用 | |
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| JP2020522281A5 (OSRAM) | ||
| JP2014511680A5 (OSRAM) | ||
| JP7458567B2 (ja) | Ｃ－ｍｅｔ結合剤 | |
| TW201904994A (zh) | 抗干擾素-γ之抗體及其應用 | |
| JP2015518857A5 (OSRAM) | ||
| JP2019509714A5 (OSRAM) |